Blending Chemistry & Biology ADC Design: Exploring Rationale- Driven Development of ALX2004 to Maximise Opportunity for Clinical Differentiation
- Highlighting design and selection of novel Topo1 payload, highlighting rationale for pairing with anti-EFGR antibody
- Presenting preclinical performance of ALX2004 including activity with improved bystander activity and stability versus deruxtecan ADCs
- Sharing rationale and design to maximise therapeutic window and overcome toxicity challenges of the class